JP2024532403A5 - - Google Patents

Info

Publication number
JP2024532403A5
JP2024532403A5 JP2024513300A JP2024513300A JP2024532403A5 JP 2024532403 A5 JP2024532403 A5 JP 2024532403A5 JP 2024513300 A JP2024513300 A JP 2024513300A JP 2024513300 A JP2024513300 A JP 2024513300A JP 2024532403 A5 JP2024532403 A5 JP 2024532403A5
Authority
JP
Japan
Application number
JP2024513300A
Other languages
Japanese (ja)
Other versions
JPWO2023028008A5 (https=
JP2024532403A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/041095 external-priority patent/WO2023028008A2/en
Publication of JP2024532403A publication Critical patent/JP2024532403A/ja
Publication of JPWO2023028008A5 publication Critical patent/JPWO2023028008A5/ja
Publication of JP2024532403A5 publication Critical patent/JP2024532403A5/ja
Pending legal-status Critical Current

Links

JP2024513300A 2021-08-23 2022-08-22 腎障害または状態の治療のためのリラキシン類似体とバソプレシン類似体との組み合わせ Pending JP2024532403A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163236090P 2021-08-23 2021-08-23
US63/236,090 2021-08-23
US202263332994P 2022-04-20 2022-04-20
US63/332,994 2022-04-20
PCT/US2022/041095 WO2023028008A2 (en) 2021-08-23 2022-08-22 Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Publications (3)

Publication Number Publication Date
JP2024532403A JP2024532403A (ja) 2024-09-05
JPWO2023028008A5 JPWO2023028008A5 (https=) 2025-08-29
JP2024532403A5 true JP2024532403A5 (https=) 2025-08-29

Family

ID=85322130

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513300A Pending JP2024532403A (ja) 2021-08-23 2022-08-22 腎障害または状態の治療のためのリラキシン類似体とバソプレシン類似体との組み合わせ

Country Status (7)

Country Link
US (1) US20240400638A1 (https=)
EP (1) EP4392440A4 (https=)
JP (1) JP2024532403A (https=)
AU (1) AU2022334113A1 (https=)
CA (1) CA3229783A1 (https=)
MX (1) MX2024002335A (https=)
WO (1) WO2023028008A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52994A (fr) * 2018-01-31 2021-05-05 Sanofi Sa Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
KR20260035823A (ko) 2023-05-18 2026-03-13 테크토닉 오퍼레이팅 컴퍼니 인코포레이티드 렐락신-2 융합 단백질 유사체 및 이를 사용하는 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015528019A (ja) * 2012-07-31 2015-09-24 ノバルティス アーゲー セレラキシンを使用する炎症の処置
CN110637027B (zh) * 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
MA52994A (fr) * 2018-01-31 2021-05-05 Sanofi Sa Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique

Similar Documents

Publication Publication Date Title
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13168U (https=)
BY13159U (https=)
BY13140U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
BY13170U (https=)